Shenzhen Shenxin Biotechnology Co., Ltd

This early-stage study tests a new mRNA vaccine called IN006 for respiratory syncytial virus (RSV) in healthy adults aged 18 to 79. The vaccine is given as one shot, with some older adults getting a booster about a year later. The main goal is to check safety and how well the vac…

This study tests a new mRNA vaccine (IN001) to prevent shingles in healthy adults aged 50 to 79. About 480 participants will receive two doses of the vaccine at different strength levels. Researchers will check how well the vaccine boosts the immune system and monitor for any sid…